Femtech company Elvie raises $80M for new product development; canine genetic company Embark snags $75M; and other digital health fundings

London-based femtech company Elvie raised $80 million in a Series C funding round led by BGF. Additional funds came from accounts managed by BlackRock Private Equity Partners, Hiro Capital, and Westerly Winds, and from existing investors Octopus Ventures and IPGL.

In addition to their participation in the round, investors Daina Spedding from BGF and Persefoni Noulika from BlackRock will join the Elvie board.

Elvie’s product portfolio includes an app-connected pelvic floor trainer called Elvie Trainer and a line of wearable breast pumps including the Elvie Pump, Elvie Catch and Elvie Curve.

The funds will be put into developing new tech-enabled products and services for women’s health, with a new addition to its product set to launch later this year. Elvie also plans on investing in company growth, operations and infrastructure.

“Elvie has already revolutionized every category it has entered – but we know that we have barely scratched the surface of what is possible for women’s tech,” Tania Boler, CEO and founder of Elvie, said in a statement.

“This further investment, alongside the wealth of expertise our new Board members bring, place Elvie in pole position to capitalize on the $50 billion femtech opportunity – and that’s only the beginning. We won’t stop until we have fulfilled our ambition to create the go-to destination for women’s health at all life stages; providing sophisticated, accurate and personalized solutions.”

Embark Veterinary, a canine genetics company, closed a Series B funding round worth $75 million. Lydia Jett of SoftBank Vision Fund 2 led the round, with F-Prime Capital, SV Angel, Slow Ventures, Freestyle Capital and Third Kind Venture Capital also participating.

The company sells DNA tests for more than 350 dog breeds that test for over 200 genetic health risks and other general physical traits to empower pet owners, veterinarians and breeders with health insights into their dogs. In addition to its Dog DNA Test, Embark is creating a database of canine health and biological information to make novel discoveries about health risks, traits and breeds.

“If there’s one thing we’ve learned over the past year, it’s that there’s nothing more important than the health of our family – and pets are a big part of our families,” Ryan Boyko, cofounder and CEO of Embark, said in a statement.

“We’re proud to be partnering with veterinarians, breeders, and dog owners all around the world to substantially increase the life and healthspan for all dogs, and – ultimately – for humans as well.”

Embark will use the funds to hire additional talent and accelerate the development of its data discovery engine. Its goal is to increase the lifespan of dogs by three years within the next decade.

Nym Health, a medical coding technology developer, scored $25 million in a round led by Addition. Other investors include GV, Dynamic Loop Capital, Tiger Global, Bessemer Venture Partners and Lightspeed, as well as angel investors Zach Weinberg and Nat Turner.

This cash, on top of Nym’s Series A from October, brings its total amount raised to $47.5 million.

Nym’s platform helps providers manage their revenue cycle by automatically assigning medical codes required for medical reimbursement. Its direct-to-billing, fully autonomous coding system is designed to reduce operational costs and health insurance rejections.

The company will put the funds towards scaling product development, increasing adoption of its platform in emergency departments and urgent care centers and growing its New York office.

Healthcare cost -transparency startup Turquoise Health announced a $5 million seed round led by Julie Yoo at a16z. Additional participants include Bessemer Venture Partners, Box Group, and angel investors Henry Ward, Megan Callahan, Jonathan Bush and NBA player Klay Thompson.

While still in beta, Turquoise is looking to make the costs of healthcare procedures more readily available in order to empower consumers to get the best price. It has a slew of products, including the Provider Rate Search, Hospital Rates Database and Clear Contracts platforms.

Turquoise did not specify where it would put the funds, but it is gearing up to add payer price data in 2022, as well as Turquoise verified provider status designations, an API and white label virtual storefronts for providers.

Oova, a Mount Sinai Health System spinout focused on fertility and women’s health, received $4.4 million in seed funding, a company spokesperson shared with MobiHealthNews. The round was led by BBG Ventures with participation by Company Ventures.

In addition to the funding, Oova has officially launched its fertility test kit, which uses urine tests and a corresponding app to track, predict and confirm ovulation.

The funds will go towards adding more testing capabilities to its kit, preparing for its market entrance and expanding into other areas of health.